logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table GPS-1. Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000 [see all tables in this series...]

Part (i) Survey methods

CountryGeographical areaYearReferenceCollection methodOriginal age rangeOriginal sample sizeAge range all adultsSample size all adultsAge range young adultsSample size young adults
BelgiumNational2008(7)InterviewAll ages1125415–64679215–342550
BulgariaNational2008(3)Interview15–64513915–64513915–342164
Czech RepublicNational2009(5)Interview15+179515–64148615–34616
DenmarkNational2010(6)Interview16+1516516–641161116–343381
GermanyNational2009(8)Multimethod18–64803018–64803018–343876
EstoniaNational2008(3)Mail15–69:15–64140115–34545
IrelandNational2006–07(5)Interview15–64496715–64:15–34:
GreeceNational (except Aegean and Ionian Islands)2004(3)Interview12–64478115–64435115–342620
SpainNational2009(8)Interview15–642010915–642010915–34:
FranceNational2005(6)Phone12–753051415–642587915–3410855
ItalyNational2008(4)Mail15–641094015–641094015–346398
CyprusNational2009(2)Interview15–64338515–64338515–341810
LatviaNational2007(2)Interview15–64450015–64450015–342497
LithuaniaNational2008(2)Interview15–64477715–64477715–342152
Luxembourg::::::::::
HungaryNational2007(3)Interview18–64271018–64271018-341111
MaltaNational2001(1)Interview18–64282818–64175518–34640
NetherlandsNational2005(3)Interview15–64451615–64451615–34:
AustriaNational2008(2)Interview15-93419615–64376115–342558
PolandNational2006(2)Interview15–64285915–64285915–342031
PortugalNational2007(2)Interview15–641220215–641220215–344765
RomaniaNational2007(2)Interview15–64679715–64679715–342262
SloveniaNational2007(1)Interview15+211715–64172415–34691
SlovakiaNational2006(6)Interview15–64130515–64130515–34556
FinlandNational2006(7)Mail15–69302915–64280215–341387
SwedenNational2008(5)Multimethod15–642209515–642209515–3416271
SwedenNational2010(12)Mail16–841006716-64731516-342196
United KingdomEngland and Wales2009-10(13)Interview16-592619916-592619916-348945
United KingdomNorthern Ireland2008-09(18)Interview16–64243816–64243816-34805
United KingdomScotland2008-09(22)Interview16+1097416–59848816–342485
United KingdomUnited Kingdom2006(24):16-59:16–59:16–34:
Croatia::::::::::
Turkey::::::::::
NorwayNational2009(3)Interview15+207315–64162415–34632

Notes:

 This table presents the methods and results for the last surveys available in each country. The number indicated in the column ‘Ref.’ is the reference to the corresponding survey in the table presenting all surveys available for each country Table GPS-0

 This table aims to present an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as a reference point for the 1993 survey. 

 ‘Data collection' means 'data collection method used in the survey': 'interview' (face-to-face interview, which may include self-completed sections for the more sensitive questions, also it may include CAPI — computer assisted interviews), 'phone' (telephone interview), 'mail' (mailed questionnaire), 'Multimethod' (Multi-Method — simultaneous use of interview, mail or internet in the same survey).  

  'Survey sample' refers to the number of actual respondents to the survey (Net sample). In some cases, national surveys cover originally a broader age range ('original age range') than that presented here for the standard groups 'All adults'(15–64) and 'Young adults' (15–34). Sample sizes are presented respectively for the 'original age range', the 'all adults' and 'young adults' groups.  

 In surveys with small sample sizes results should be interpreted with caution. 

 Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15–64, young adults: 15–34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. 

 For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions.  

 See also 'General notes for interpreting data' on the Explanatory notes and help page

Sources:

 See Table GPS-0

 For more details on methodological features for each survey, see Table GPS-121

(see the help page for information about formats etc.)

Page last updated: Thursday, 14 July 2011